Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2 Non-squamous Non-small-cell Lung Cancer 1 Non Squamous Non Small Cell Lung 1 Neoadjuvant Therapy 1 Gastrointestinal Stromal Tumors 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced NSCLC 1

Interventions

Fluorouracil 131 Leucovorin 127 Oxaliplatin 93 Bevacizumab 86 Irinotecan 74 Capecitabine 63 Cetuximab 47 Folfox protocol 32 Panitumumab 18 regorafenib 16 trifluridine tipiracil drug combination 15 Drug Therapy 14 Chemotherapy, Adjuvant 13 IFL protocol 10 Floxuridine 10 Radiotherapy 9 Tegafur 7 Neoadjuvant Therapy 7 Levoleucovorin 7 Laparoscopy 7 Aspirin 7 pembrolizumab 6 atezolizumab 6 Trifluridine 6 Celecoxib 6 XELOX 5 Mitomycin 5 Colonoscopy 5 tipiracil 4 sintilimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colorectal Neoplasms × famitinib × Clear all

NCT02390947 2020-12-22

FACT

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡